Duchenne muscular dystrophy (DMD) is the most common lethal muscle disorder in children. It is caused by mutations of the dystrophin gene. Adeno-associated virus (AAV)-mediated gene replacement therapy has been actively pursued to treat DMD. However, this promising therapeutic modality has been challenged by the small packaging capacity of the AAV vector. The size of the full-length dystrophin cDNA is >11 kb, while an AAV virus can carry only a 5 kb genome. Innovative high-capacity AAV vectors may offer an opportunity to express the full-length dystrophin coding sequence. Here we describe several sets of tri-AAV vectors for full-length human dystrophin delivery. In each set, the full-length human dystrophin cDNA was split into three fragments and independently packaged into separate recombinant AAV vectors. Each vector was engineered with unique recombination signals for directional recombination. Tri-AAV vectors were coinjected into the tibialis anterior muscle of dystrophin-deficient mdx4cv mice. Thirty-five days after injection, dystrophin expression was examined by immunofluorescence staining. Despite low reconstitution efficiency, full-length human dystrophin was successfully expressed from the tri-AAV vectors. Our results suggest that AAV can be engineered to express an extra-large (up to 15 kb) gene that is approximately three times the size of the wild-type AAV genome. Further optimization of the trivector strategy may expand the utility of AAV for human gene therapy.
BartoliM., PoupiotJ., GoyenvalleA., et al. (2006). Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther., 13, 20–28.
3.
BostickB., GhoshA., YueY., et al. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther., 14, 1605–1609.
4.
BuningH. (2013). Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol. Med., 5, 1–3.
ChamberlainJ.S. (1997). Dystrophin levels required for correction of Duchenne muscular dystrophy. Basic Appl. Myol., 7, 251–255.
7.
CrawfordG.E., FaulknerJ.A., CrosbieR.H., et al. (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol., 150, 1399–1410.
8.
DankoI., ChapmanV., and WolffJ.A. (1992). The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr. Res., 32, 128–131.
9.
DongJ.Y., FanP.D., and FrizzellR.A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther., 7, 2101–2112.
10.
DongB., NakaiH., and XiaoW. (2010). Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther., 18, 87–92.
11.
DuanD. (2011). Duchenne muscular dystrophy gene therapy: lost in translation?. Res. Rep. Biol., 2, 31–42.
12.
DuanD., YueY., and EngelhardtJ.F. (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther., 4, 383–391.
13.
EnglandS.B., NicholsonL.V., JohnsonM.A., et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 343, 180–182.
14.
GhoshA., YueY., and DuanD. (2006). Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med., 8, 298–305.
15.
GhoshA., YueY., LaiY., and DuanD. (2008). A hybrid vector system expands aden-associated viral vector packaging capacity in a transgene independent manner. Mol. Ther., 16, 124–130.
16.
GhoshA., YueY., and DuanD. (2011). Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequence. Hum. Gene Ther., 22, 77–83.
17.
HarperS.Q., HauserM.A., DellorussoC., et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8, 253–261.
18.
KoenigM., BeggsA.H., MoyerM., et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet., 45, 498–506.
19.
KooT., MalerbaA., AthanasopoulosT., et al. (2011). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther., 22, 1379–1388.
20.
KooT., PopplewellL., AthanasopoulosT., and DicksonG. (2014). Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther., 25, 98–108.
21.
LaiY., and DuanD. (2012). Progress in gene therapy of dystrophic heart disease. Gene Ther., 19, 678–685.
22.
LaiY., YueY., LiuM., et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol., 23, 1435–1439.
LaiY., ThomasG.D., YueY., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest., 119, 624–635.
25.
LaiY., YueY., BostickB., and DuanD. (2010a). Delivering large therapeutic genes for muscle gene therapy. In Muscle Gene Therapy. DuanD., ed. (Springer Science+Business Media, LLC, New York) pp. 205–218.
26.
LaiY., YueY., and DuanD. (2010b). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome>or=8.2 kb. Mol. Ther., 18, 75–79.
27.
LaiY., ZhaoJ., YueY., and DuanD. (2013). alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. USA, 110, 525–530.
28.
MaysL.E., and WilsonJ.M. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther., 19, 16–27.
29.
MingozziF., and HighK.A. (2011a). Immune responses to AAV in clinical trials. Curr. Gene Ther., 11, 321–330.
30.
MingozziF., and HighK.A. (2011b). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet., 12, 341–355.
31.
OdomG.L., GregorevicP., AllenJ.M., and ChamberlainJ.S. (2011). Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther., 19, 36–45.
32.
PanX., YueY., ZhangK., et al. (2013). Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8. Hum. Gene Ther., 24, 584–594.
33.
PhelpsS.F., HauserM.A., ColeN.M., et al. (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet., 4, 1251–1258.
34.
QiaoC., ZhangW., YuanZ., et al. (2010). AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther., 21, 1343–1348.
35.
RumeurE.L., HubertJ.F., and WinderS.J. (2012). A new twist to coiled coil. FEBS Lett., 586, 2717–2722.
36.
ShinJ.H., YueY., and DuanD. (2012). Recombinant adeno-associated viral vector production and purification. Methods Mol. Biol., 798, 267–284.
37.
SrivastavaA., LusbyE.W., and BernsK.I. (1983). Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol., 45, 555–564.
38.
Taghli-LamallemO., JaglaK., ChamberlaincJ.S., and BodmerR. (2014). Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila. Exp. Gerontol., 49, 26–34.
39.
XuZ., YueY., LaiY., et al. (2004). Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Hum. Gene Ther., 15, 896–905.
40.
YueY., and DuanD. (2002). Development of multiple cloning site cis-vectors for recombinant adeno- associated virus production. Biotechniques, 33, 672, 674, 676–678.
41.
YueY., LiZ., HarperS.Q., et al. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation, 108, 1626–1632.
42.
YueY., GhoshA., LongC., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther., 16, 1944–1952.
43.
YueY., ShinJ.-H., and DuanD. (2011). Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol. Biol., 709, 313–329.
44.
ZhangY., and DuanD. (2012). Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther., 23, 98–103.
45.
ZhangY., YueY., LiL., et al. (2013). Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet., 22, 3720–3729.
46.
ZhongL., LiB., MahC.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA, 105, 7827–7832.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
